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Abstract
Background: Cyclin-dependent kinases 2, 4 and 6 (Cdk2, Cdk4, Cdk6) are closely structurally homologous proteins
which are classically understood to control the transition from the G1 to the S-phases of the cell cycle by
combining with their appropriate cyclin D or cyclin E partners to form kinase-active holoenzymes. Deregulation of
Cdk4 is widespread in human cancer, CDK4 gene knockout is highly protective against chemical and oncogene-
mediated epithelial carcinogenesis, despite the continued presence of CDK2 and CDK6; and overexpresssion of
Cdk4 promotes skin carcinogenesis. Surprisingly, however, Cdk4 kinase inhibitors have not yet fulfilled their
expectation as ‘blockbuster’ anticancer agents. Resistance to inhibition of Cdk4 kinase in some cases could
potentially be due to a non-kinase activity, as recently reported with epidermal growth factor receptor.
Results: A search for a potential functional site of non-kinase activity present in Cdk4 but not Cdk2 or Cdk6
revealed a previously-unidentified loop on the outside of the C’-terminal non-kinase domain of Cdk4, containing a
central amino-acid sequence, Pro-Arg-Gly-Pro-Arg-Pro (PRGPRP). An isolated hexapeptide with this sequence and its
cyclic amphiphilic congeners are selectively lethal at high doses to a wide range of human cancer cell lines whilst
sparing normal diploid keratinocytes and fibroblasts. Treated cancer cells do not exhibit the wide variability of dose
response typically seen with other anticancer agents. Cancer cell killing by PRGPRP, in a cyclic amphiphilic cassette,
requires cells to be in cycle but does not perturb cell cycle distribution and is accompanied by altered relative
Cdk4/Cdk1 expression and selective decrease in ATP levels. Morphological features of apoptosis are absent and
cancer cell death does not appear to involve autophagy.
Conclusion: These findings suggest a potential new paradigm for the development of broad-spectrum cancer
specific therapeutics with a companion diagnostic biomarker and a putative functional site for kinase-unrelated
activities of Cdk4.
Keywords: Cdk4, non-kinase, proteomic, PRGPRP, programmed cell death, selective anticancer, broad spectrum
Background
Cdk4 has been actively pursued, over the last two dec-
ades, as a promising anticancer drug target [1,2] based
on its role in cell cycle control [3] and its widespread
deregulation in a multiplicity of different tumours [4].
Single agent activity of cyclin dependent kinase inhibi-
tors in general has, however, been disappointing, with
low percentages of objective responses [5], and no Cdk
inhibitor has yet been approved as an anticancer drug
[6] In particular, the specific Cdk4 inhibitor, flavopiridol,
yielded no objective responses in phase II studies of
metastatic melanoma, endometrial adenocarcinoma and
multiple myeloma [7] when used as a single agent. Fol-
lowing encouraging animal studies [8], newer Cdk4
kinase inhibitors such as PD 0332991, are now entering
clinical trials in combination with agents of already pro-
ven activity such as bortezomib rather than as single
agents. Nonetheless, CDK4 gene knockout in mice
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completely abrogates chemically induced epidermal car-
cinogenesis [9], without effect on normal skin keratino-
cyte proliferation, despite the continuing presence of
Cdk2 and Cdk6. Conversely low levels or absence of
Cdk6 do not prevent the in-vitro growth of human
breast cancer cell lines [10]. Additionally, ablation of
CDK4 [11] but not of CDK2 [12] inhibits myc-mediated
oral tumorigenesis. Furthermore, overexpression of
Cdk4 but not cyclin D1 promotes mouse skin carcino-
genesis [13], whilst elevated Cdk2 activity, despite indu-
cing keratinocyte proliferation, is not tumorogenic [14].
Cdk4 would therefore appear to be the key cyclin-
dependent kinase for both chemical and oncogene pro-
moted epithelial carcinogenesis. The poor activity of
drugs directed against Cdk4 kinase is thus surprising.
The paradigm relating cell cycle control, cyclin-
dependent kinases and cancer has changed from our
classical understanding, however, with reappraisal of
the mandatory requirement of Cdk2, Cdk4 or Cdk6 for
normal cell division [15]. Moreover, Cdk4 and Cdk6
have been shown to differ functionally from one
another in several respects [16-19] and Cdk4 has been
reported to be closely co-expressed with Cdk1 in a
wide range of human cancers in-vitro and in malignant
melanoma in the clinic but not in normal diploid
fibroblasts or keratinocytes [20]. Evidence is also now
accumulating that Cdk4 can exhibit kinase-unrelated
activities. Direct interaction of Cdk4 with Myo-D to
restrict myoblast differentiation in the absence of Cdk4
kinase activity has been reported [21] and mutant,
kinase-dead, CDK4-N158D upregulation in TIG3 cells
can induce p16INK4 expression equally as well as
kinase-active, wild-type CDK4 [22]. Recently, resistance
to EGFR tyrosine kinase inhibitors, in PCMM2 pros-
tate cancer cells, has been reported to be related to a
kinase-independent function of EGFR which prevents
autophagy by maintaining intracellular glucose levels
[23]. Possibly the apparent discordance between results
from CDK4 knockout cancer models, and Cdk4 kinase
inhibitor studies could stem from such critical kinase-
independent activities of Cdk4.
Divergent roles for Cdk4 and Cdk6 and evidence of
kinase-unrelated activities in cyclin-dependent and other
kinases along with the differences between Cdk4 and Cdk2
or Cdk6 in promoting carcinogenesis, prompted a search
for a functional site of kinase-independent activity specific
to Cdk4 but not Cdk2 or Cdk6. Binding sites for proteins
intrinsic to classical Cdk4 kinase activity all lie predomi-
nantly within the N’-terminal 2/3 of the Cdk4 protein.
Structural studies of the whole Cdk4, Cdk6 and Cdk2
molecules were therefore carried out to search for a poten-
tial kinase-independent functional site within the C’-term-
inal domain of Cdk4, not shared by Cdk6 or Cdk2. These
studies revealed a previously-undescribed, proline/arginine
rich, 12 amino-acid site, FPPRGPRPVQSV, on the outside
surface of Cdk4.
Proteomic expression levels of Cdk1 and Cdk4 are
closely correlated in human cancers but not normal
cells [20] and have been shown to spontaneously go up
and down together from experiment to experiment in
several human cancer cell lines [24]. Cdk4 overexpres-
sion following transfection is accompanied by concomi-
tant increase in Cdk1 expression in RAMA37 cells [20]
and disruption of Cdk1/Cdk4 co-expression can be
observed in human cancer cells undergoing spontaneous
cell death [25]. Possibly the FPPRGPRPVQSV region of
Cdk4 might be involved in control of Cdk1 expression.
Such a mechanism could be vulnerable to competitive
inhibition, disrupting the Cdk1/Cdk4 co-relationship
and potentially destabilising malignant cells. To test this
possibility, human cancer cells were exposed to peptide
fragments of varying length derived from the
FPPRGPRPVQSV sequence and the effects on cell pro-
liferation and relative Cdk1/Cdk4 levels monitored.
Results
Proteomic co-expression of Cdk1/Cdk4 in human cancer
cell lines is not seen with Cdk1/Cdk2 or Cdk1/Cdk6
Figure 1 compares proteomic expression of Cdk1 to
Cdks 2, 4 and 6 using linear regression analysis across
16 human in-vitro cell lines, covering a wide range of
histological subtypes. Only Cdk4 has a highly significant
co-expressive relationship with Cdk1.
Previous experiments have demonstrated a causal rela-
tionship between Cdk4 and Cdk1 expression in 10 posi-
tive clones from RAMA37 cells transfected with CDK4
cDNA [20]. To confirm this relationship in a different
system, an ecdysone-inducible CDK4 expression vector
was introduced to 2780 human ovarian carcinoma cells
and positive transfectants selected. Induction of exogen-
ous Cdk4 expression by 1 μM muristerone (Figure 1B)
in this system, was accompanied by contemporaneous
increase in Cdk1 protein. In addition there was no
change in the phosphorylation status of the retinoblas-
toma protein.
Modelling studies
Prior to recent reports [4,26] of a crystal structure for
Cdk4, it was necessary to use the considerable sequence
homology across the Cdk protein family to produce a
comparative model. Related sequences and important
regions within the Cdk4 molecule were identified, a
model of Cdk4 based on experimentally determined
structures of Cdk6 and Cdk2 was built and regions in
the Cdk4 model that might provide support for a
kinase-unrelated binding site were sought. Although the
protein data bank contained a model structure for Cdk4
(1LD2), an independent model was built which might
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provide advantageous additional insights. Sequence
alignment of Homo Sapiens Cdk4 with a range of Cdk4
sequences from mammalian and non-mammalian organ-
isms was initially performed.
For the N’-terminal half of the non-mammalian
sequences of Cdk4, corresponding to the first domain and
responsible for the majority of its function, the sequence is
well conserved. However, the C’-terminal third of the
sequence showed considerable variability. In particular,
our attention was drawn to the FPPRGPRPVQSV
sequence in Homo Sapiens Cdk4 which showed little or
no conservation beyond mammalian species.
Sequence alignment of Cdk4, 6, and 2, showed consid-
erable conservation between all three proteins, as
expected. The 12mer segment previously identified in
the alignment of mammalian and non-mammalian Cdk4
sequences, however, exhibited very little homology with
either Cdk6 or Cdk2 (also apparent in data from an
independent Cdk modelling exercise [27]), again sug-
gesting that it might have a unique functional role. In
addition to Cdk4, a search of the protein database for
similar sequences to “FPPRGPRPVQSV” only returned
Ras GTPase-activating protein-binding protein 2 for
which there is, at present, no structural data.
An homology model of Cdk4 was built using a combi-
nation of Cdk2 and Cdk6 protein structures as tem-
plates. Missing segments of the sequence, and in some
cases, crystal packing contacts, in the majority of struc-
tures used, may have affected the conformations
adopted. Thus the quality of any derived homology
model could be suboptimal. For the purposes of this
study, however, it was reasonable to expect the model
to provide reliable information on the tertiary structure,
the location of amino acids within the structure, and
whether or not they are solvent accessible. Five homol-
ogy model structures of Cdk4 were initially constructed,
with that using the Cdk6 template 1BLX being consid-
ered the most reliable (Table 1). The loop containing
the previously identified 12mer (the central hexamer of
which, PRGPRP, is shown in all-atom detail in cartoon
representation [28] (Figure 1C) is solvent accessible in
all models and varies only slightly in conformation. This
sequence is situated in domain 2 (amino acid residues
249 - 260) at the furthest point away from domain 1
and differs from that of Cdk2 and Cdk6 in being rich in
arginine and proline. The bioinformatics and structural
evidence together, suggests this sequence as a plausible
candidate for a kinase-independent functional site. Our
structural modelling is validated by the recently pub-
lished crystal structure data [4,26].
An isolated hexapeptide, homologous with the central
sequence of the FPPRGPRPVQ external Cdk4 loop, kills
human RT112 bladder cancer cells but not normal diploid
human fibroblasts
A broad search for possible biological activity associated
with the FPPRGPRPVQSV peptide sequence was initially
instituted by screening human bladder cancer cell lines
for potential in-vitro morphological changes, compared
to control cultures of normal diploid human fibroblasts
at 4-8 passages from primary culture as controls. A range
of linear N’-capped, synthetic peptides matching 4 - 10
amino acid lengths of the sequence FPPRGPRPVQSV
were prepared as amides (Polypeptide Ltd). The peptides
were dissolved, over a range of concentrations, in Ham’s
F12 + 10% FCS and introduced in 100 μL quantities to
microwells containing 500 RT112 bladder cancer cells, or
normal diploid human fibroblasts, in 200 μL of Ham’s
F12 + 10% FCS plated 24 hours earlier on 96 well plates.
The whole FPPRGPRPVQ peptide (Table 2,I) was found
to be selectively toxic to RT112 human bladder cancer
cells, at a concentration of 1.0 mM, with partial sparing
of normal fibroblasts. A hexapeptide PRGPRP and a pen-
tapeptide RGPRP homologous to the central region of
FPPRGPRPVQ, showed greater selective toxicity to
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Figure 1 A potential protein-protein non-kinase functional
binding site in Cdk4 not present in Cdk2 or Cdk6. A - Relative
proteomic expression by Western blotting, of Cdk4, Cdk6 and Cdk2
compared to Cdk1 on 16 human in vitro cancer cell lines of widely
differing histological subtype by quantitative Western blotting as
previously described [20]. Primary antibodies were Cdk1 - mouse
monoclonal sc-54 (1/250), Cdk2 - (M2) rabbit polyclonal sc-163 (1/
250), Cdk4 - rabbit polyclonal sc-260 (1/250) Cdk6 - rabbit polyclonal
sc-260 at 1/250, (see methods). B - Upper panels: Endogenous Cdk1
follows a similar time course and increase in proteomic expression
as exogenous Cdk4 induced by 1 μM muristerone in 2780 pvrg-
pINDK4 clone 1D cells (see methods). Lower panels Western
blotting for total retinoblastoma protein (pRb 105) and
hyperphosphorylated retinoblastoma protein (p110) following
exposure of 2780 pvrgpINDK4 clone 1D cells to 1 μM muristerone.
C - Location of the PRGPRP central hexameric amino acid sequence
(residues 249 - 260) of FPPRGPRPVQS within an externalised loop in
the C’ terminal region, distant from the classically described kinase
domain of Cdk4.
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Table 1 Quality and accuracy scores for the built models
MODEL Model
1
Model
2
Model 3 Model 4 Model 5
Template 1BLX
(CDK6)
1G3N
(CDK6)
Base template 1BLX, Variable regions differing
by more than 2.0 Å rmsd modelled from
1G3N, 1BI8, 1BI7 and 1JOW (all CDK6)
Base template 1BLX, Variable
regions differing by more
than 2.0 Å rmsd. modelled
from 1HCL (CDK2)
Base template 1BLX, Variable
regions differing by more
than 2.0 Å rmsd. modelled
from 1GII (CDK2)
Threading score 165.6 158.2 151.0 128.8 99.7
Molecular
mechanics
energy (kJ mol-1)
-12203.3 -12526.1 -12182.5 -11900.3 -11795.5
RMS deviation
from 1BLX (in Å)
0.48 0.88 0.62 0.67 0.65
Structure Z-scores,
positive is better
than average
2nd generation
packing quality
-1.093 -0.868 -0.964 -1.090 -1.228
Ramachandran
plot appearance
-2.573 -3.374 -2.837 -2.965 -3.104
c-1/c-2 rotamer
quality
-1.148 -1.470 -1.340 -0.955 -0.968
Backbone
conformation
-6.485 -5.201 -5.637 -7.016 -7.564
RMS Z-scores,
should be close
to 1
Bond lengths 0.655 0.645 0.652 0.657 0.668
Bond angles 1.187 1.176 1.183 1.168 1.181
Omega angle
restraints
1.354 1.159 1.413 1.478 1.396
Side chain
planarity
1.608 1.667 1.494 1.277 1.292
Improper
dihedral
distribution
0.883 0.882 0.907 0.879 0.865
Inside/Outside
distribution
1.019 1.038 1.025 1.043 1.051
A high threading score indicates a better fit of the sequence in the structure. A low molecular mechanics energy indicates a more relaxed structure.
Structural Z-scores less than -2.0 indicate problems in the model, scores less then -4.0 indicates serious errors. RMS Z-scores should be close to 1.0.
Table 2 In-vitro Survival of RT112 Human Bladder Cancer and Normal Diploid Human Fibroblasts
Cell Viability
Compound Dose Human Bladder Cancer Normal Diploid Fibroblasts
I. FPPRGPRPVQ 1.0 mM +/- + +/-
II. (THR1) PRGPRP 5.0 mM - - - + + + + +
III. PRGPR 5.0 mM - - - + + +
IV. RGPRP 5.0 mM +/- + + +
V. RGPR 5.0 mM + + + + + +
VI. PRRPGP 5.0 mM + + + + + +
VII. PEGPRP 5.0 mM + + + + + +
VIII. PRGPEP 5.0 mM + + + + + +
IX. PEGPEP 5.0 mM + + + + + +
(+++ = same morphological appearance as untreated contros, — = total morphological cell death. See Figure 2A for typical examples).
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RT112 human bladder cancer cells whilst sparing normal
diploid fibroblasts at concentrations of 5 mM (Table 2,
II). Morphological analysis demonstrated PRGPRP stimu-
lates normal fibroblast growth whilst showing high toxi-
city against RT112 cells (Figure 2A). Figure 2C shows
representative colony survival assays of PRGPRP-treated
RT112 cells. Shorter linear peptides such as RGPR were
inactive and cells exposed to them grew with similar
morphological appearances to untreated controls. (Table
2,V). Similar results (not shown) were obtained with the
MGHU1 human bladder cancer cell line.
PRGPRP cell killing is specific for cancer cells and is
amino-acid sequence dependent
The amino acid sequence within the hexapeptide is cri-
tical for cancer cell lethality. Thus transposing one of
the two arginines, to give PRRPGP rather than PRGPRP,
markedly diminishes RT112 human bladder cancer cell
killing (Table 2,VI). Moreover, PEGPRP and PRGPEP, in
which the arginines were substituted by glutamic acids,
both lacked cytotoxic activity against RT112 and had no
effect on normal diploid human fibroblasts (Table 2,VII-
IX). The selective anticancer activity of PRGPRP as
compared to PRRPGP was confirmed by clonogenic
assays on RT112 (Figure 3C).
Cyclic amphiphilic constructs containing the PRGPRP
amino-acid sequence show specific activity at micromolar
concentrations and a shorter time to cell death
Attempts to limit proteolysis and improve cell uptake, by
incorporating the hexameric peptide sequence into cyclic
peptide cassettes were undertaken, initially without suc-
cess (Table 3,X-XIII). Linear constructs attaching PRGPRP
to a known cell-internalising amphiphilic sequence [29]
were also unsuccessful (Table 3,XIV and 3XV). Combining
the two approaches to create cyclic amphiphilic peptide
cassettes, however, resulted in a number of peptides with a
fifty- to a hundred-fold improvement in selective cancer
cell cytotoxicity (Table 4,XVI, XVIII, XIX & Figures 2C
&3A). Cell killing by THR53, THR54 and THR79, of the
RT112 human bladder cancer and H460 human non-
small lung cancer cell lines, was seen at concentrations of
50 μM - 200 μM (Table 4 & Figures 3A, B) and, for the
majority of cell lines, reached a maximum within 4 days
(Figures 4A, 5C). Selective toxicity to these cancer cell
lines, and not normal fibroblasts, was retained (Table 4).
Importance of arginines in the cancerocidal activity of
PRGPRP-containing cyclin amphiphilic peptides
The previously observed, arginine-related, structure/
function relationship to PRGPRP at 5 mM (Table 2,II vs.
2,VII & Figure 3C) was retained in the cyclic amphiphilic
compounds (Compare survival of H460 cells exposed to
THR53 or THR53C Figures 3D, 4C). Additionally N-
mono-methylation within the guanidium moiety of the
arginines (Table 4,XX-XXII) removed the cytotoxic activ-
ity of THR54 against H460 cells.
THR53 kills a wide range of human cancer cells but not
MRC5-hTERT immortalised fibroblasts or human diploid
keratinocytes
After exposure to 200 μM THR53, widely histologically
different human cancer cell lines all exhibited closely simi-
lar morphological changes at 5 days (Figure 4B), followed
by complete lethality in clonogenic assays at 15 days. The
appearances of the disintegrating colonies in Figure 4B
were not dissimilar to those of “starbursts” earlier reported
[25] in human in vitro cancer cell colonies undergoing
spontaneous cell death. Table 5 lists 11 cell lines with
complete response to 200 μM THR53. This relatively
homogeneous therapeutic response to the same critical
dose of THR53 markedly contrasts with the wide range of
variability of in-vitro dose response of different cancer cell
lines typically seen with conventional chemotherapeutic
agents [30] In addition to showing lack of toxicity towards
normal human diploid fibroblasts, THR53 and related cyc-
lic amphiphilic PRGPRP-containing peptides were not
cytotoxic to normal diploid human keratinocytes growing
as primary cultures (Figure 2B) or to MRC5-hTERT
immortalised fibroblasts (Figures 4A and 5A).
Time course and morphological changes of MRC5-hTERT
and cancer cells exposed to 200 μM THR53
On time lapse photomicrography following exposure to
THR53 (Figures 5B, C), dying RT112 and H460 cancer
cells exhibited morphological features of increased vacuo-
lation followed by swelling and disintegration, as opposed
to the membrane blebbing and pyknosis which typify
apoptosis. Progressive morphological changes in dying
H460 cells exposed to 200 μM THR53 [additional file 1],
contrasted with progressive cell division in untreated
H460 cells [additional file 2] are shown as videos. Immor-
talised MRC5-hTERT fibroblasts, were unaffected by
exposure to 200 μM THR53 except for some generalised
slowing of growth (Figure 5A), [additional file 3] as com-
pared to control, untreated, MRC5-hTERT cells [addi-
tional file 4]. RT112 cells were more sensitive to THR53
than H460 cells and died within 30 - 40 hours as com-
pared to 96 hours for H460 and the majority of other
human cancer cell lines investigated. For example H1299
human non-small cell lung cancer and MCF-7 breast
cancer cells exhibited the same time course to death and
morphological changes as H460 (Figures 4A and 4B).
THR53 anticancer activity is dependent on cells being in
cycle
THR53 had no effect on serum-deprived, MCF7 breast
cancer cells (in medium + 0.1%FCS) whereas cycling
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Control PRGPRP
RT112 Human
Bladder Cancer
Control PRGPRP
Normal Diploid
Human Fibroblasts
Normal Fibroblasts
Control THR53
H460 Human Non-Small
Cell Lung Cancer
Control THR53
Normal Diploid
Human Keratinocytes
Control
Treated
RT112 + PRGPRP (5mM) H460 + THR53 (200 M)
A
B
C
+++ - - -
RT112 Human Bladder Cancer
+++ ++++
Normal Diploid Human Fibroblasts
Figure 2 Selective in-vitro cell killing of human cancer cells by exposure to linear N’-capped PRGPRP-amide and the derived cyclic
amphiphilic analogue, THR53. (cyc-[FPPRGPRPVKLALKLALK]) A Photomicrographs illustrating typical in-vitro morphological appearances of
RT112 human bladder cancer cells (Left hand panels) and normal human fibroblasts (Right hand panels) following exposure to 5.0 mM PRGPRP
(Ac-Pro-Arg-Gly-Pro-Arg-Pro-NH2) or control nonsense peptide. PRGPRP causes complete necrosis of RT112 bladder cancer cells but increases the
confluent cell density of normal diploid fibroblasts (Magnification ×40). B. Photomicrographs illustrating typical in-vitro morphological
appearances of NCI-H460 human non-small cell lung cancer cells (Left hand panels) and normal diploid human keratinocytes (Right hand panels)
following exposure to 200 μM THR53 or control nonsense peptide. (Magnification × 40) C. Macroscopic appearances of clonogenic assay tissue
culture wells of RT112 human bladder cancer cells exposed to 5 mM PRGPRP (left hand panels) and H460 human non-small cell lung cancer
cells exposed to 200 μM THR53 (right hand panels).
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MCF-7 cells in medium +10% FCS were killed (Figure 6A),
indicating that MCF-7 cells needed to be in cycle to be
killed. Cell death, however, was not dependent on cell divi-
sion in MCF-7, RT112 or H460. THR53 had no effect on
cell cycle phase distribution in H460 cells (Figure 6B) and
PRGPRP hexapeptide cancer cell killing was unrelated to
endogenous levels of Cdk4 or Cyclin D1. For example
MGHU1 human bladder cancer and G361 human mela-
noma cells both exhibited total cell death with the same
dose of 200 μM THR53 but respectively had markedly
different endogenous Cdk4 values of 3.605 ± 0.735 and
6.035 ± 1.765 and Cyclin D1 values of 3.465 ± 0.832 and
1.055 ± 0.292 [24].
The Cdk1/Cdk4 ratio changes following exposure to
PRGPRP and THR53
Cdk1 and Cdk4 have been shown to have closely corre-
lated expression across a wide range of human cancer
cell lines [20]. This co-expression is unaffected by cyto-
cidal doses of cisdiamminedichloroplatinum [24] but
can accompany spontaneous cancer cell death [25].
Whether or not Cdk1/Cdk4 co-expression remained
constant in cancer cells dying as a result of exposure to
PRGPRP was thus examined by Western blotting. After
exposure to PRGPRP, but not PRRPGP, RT112 cells
showed a progressive rise over 10 days in Cdk1 expres-
sion compared to Cdk4 (Figure 6C). Similar results were
obtained after exposure to 200 μM THR53 (Figure 6D),
with complete disappearance of Cdk4 at 24 hours.
These results suggest a potential role for PRGPRP in
modulating Cdk4/Cdk1 co-expression in parallel with
cancer cell killing and point to the possibility of the
Cdk1/Cdk4 ratio as being a potential companion thera-
nostic biomarker for PRGPRP anticancer activity.
100 μM THR53 causes depletion of ATP in dying H460
cells but does not induce autophagy
In order to probe the mechanism of PRGPRP analogue
induced cell death, three assays were conducted on
RT112 Human Bladder Cancer
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Figure 3 Clonogenic cell survival assays of RT112 human
bladder cancer cells and H460 human non-small cell lung
cancer cells exposed to PRGPRP vs PRRPGP as linear
hexapeptides or in cyclic amphiphilic cassettes. A. Comparison
of response of RT112 human bladder cancer cells to PRGPRP and
THR53. B. Clonogenic cell survival of H460 human non-small cell
lung cancer cells to THR53 (cyc-[FPPRGPRPVKLALKALAK]); THR54
(cyc-[PRGPRPVALKLALKLAL]) and THR79 (cyc-[PRGPRPvalklalkalal]).
(Capitals signify L-amino acids, lower case signify D-amino-acids). C.
Comparative clonogenic cell survival of RT112 human bladder
cancer cells exposed to the linear end-capped hexapeptides
PRGPRP or PRRPGP. D. Comparative clonogenic cell survival of H460
human non-small cell lung cancer cells exposed to the cyclic
amphiphilic peptides: THR 53 (cyc-[FPPRGPRPVKLALKALAK]) or THR
53C (cyc-[FPPRRPGPVKLALKALAK]).
Table 3 In-vitro Survival of H460 Human Non-small Cell Lung Cancer and Normal Diploid Human Fibroblasts Following
Exposure to Cyclic Non-Amphiphilic or Linear Amphiphilic Analogues of PRGPRP
Cell Viability
Compound Dose Human Non-small Cell Lung Cancer Normal Diploid Fibroblasts
X. Cyc-[AAAGGGPRGPRPGGGAAA] 200 μM + + + + + +
XI. Cyc-[GGGGGGPRGPRPGGGGGG] 200 μM + + + + + +
XII. Cyc-GGGGGGPRGPRPGGGGGG] 200 μM + + + + + +
XIII. Cyc-[AAGPGGPRGPRPGGPGAA] 200 μM + + + + + +
XIV. Linear FPPRGPRPVKLALKLALK 200 μM + + + + + +
XV Linear PRGPRPVALKLALKLAL 200 μM + + + + + +
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H460 human non-small cell lung cancer cells over a
period of 96 hours following exposure to THR53 (Figure
7A). Total cellular protein was measured by sulphorho-
damine B [31], mitochondrial oxidation/reduction was
measured by Alamar Blue assay [32] and cellular ATP
level was measured by luciferase activity [33]. A dose of
100 μM THR53 at which 50% of H460 cells were killed
by 96 hours was chosen for assay comparison. Figure
7A shows progressive diminution of ATP levels between
48 and 96 hours after 100 μM THR53 without change
in total cellular protein or altered mitochondrial oxida-
tion/reduction. This selective ATP inhibition contrasts
with the ubiquitous effect of chloroquine on all three
parameters (figure 7B). Following exposure to THR53,
morphological characteristics of apoptosis were not seen
in the time lapse experiments, (Figures 5B and 5C) or in
sub-G1 DNA content on cell cycle profile analysis;
rather the cellular morphology of THR53 treated cells
suggested death was either by necrosis or autophagy. An
assay for autophagy was thus carried out which utilises
a proprietary reagent (Cyto-ID Green) that specifically
labels autophagolysosomes, co-localising with LC3, a
specific autophagosome marker [34]. 25 μM Chloro-
quine was used as a positive control agent known to
induce autophagy. In the cells stained with Cyto-ID
Green, there was a clear rightward shift in the FL-1
peak at both 72 h and 96 h following chloroquine treat-
ment, indicating an increase in autophagy in these cells.
However, no difference in the mean fluorescent intensity
was seen following treatment with 100 μM THR53 at
either 72 h or 96 h, when compared with control.
Trypan blue assay for necrosis in H460 and H1299 human
non-small cell lung cancer cells and MCF-7 human breast
cancer cells
The absence of autophagy in H460 cells indicates that
this mode of cell death is unlikely to provide a general
explanation for the selective lethality of PRGPRP com-
pounds against human cancer cells. Necrosis is charac-
terised by loss of cell membrane integrity. Viable cells
do not incorporate trypan blue. Failure to exclude this
dye reflects a loss of plasma membrane integrity asso-
ciated with necrosis [35].
Figure 4A shows THR53 induces necrosis, as detected
by trypan blue uptake, in all 3 human cancer cell lines
but not in MRC5-h-TERT immortalised fibroblasts. The
time courses of appearance of necrotic cells are closely
similar for all three human cancer cell lines, being initi-
ally detectable at day 3 and progressively increasing over
the following 4 days at comparable rates. In each case
there is a parallel diminution in the percentage of viable
cells. The ability to induce necrosis as identified by fail-
ure of trypan blue exclusion is dependent on the hexa-
peptide amino-acid sequence; being present with the
amphiphilic cyclised polymer THR53 which carries
PRGPRP but not with THR53C which carries PRRPGP
(Figure 4C).
Discussion
Small peptides containing the PRGPRP amino-acid
sequence are selectively toxic to a wide range of cancer
cells whilst sparing normal cells
The amino-acid sequence Pro-Arg-Gly-Pro-Arg-Pro
(PRGPRP) within small peptides is selectively canceroci-
dal towards a wide range of human in-vitro cancer cell
lines but not normal diploid human keratinocytes, fibro-
blasts or immortalised MRC5-hTERT cells. The ubiqui-
tous, selective anticancer activity is highly dependent on
the arginines within the hexapeptide sequence, because
alteration of the amino acid sequence to Pro-Arg-Arg-
Pro-Gly-Pro removes the cancerocidal capacity as does
substitution of the arginines for glutamic acid or L-NG-
monomethyl-arginine. The lack of toxicity of PRGPRP
compounds for non-cancerous cells and the removal of
anticancer activity by modulation of the arginines in
PRGPRP indicate that, although used here in high con-
centration, these compounds do have a truly selective
cancerocidal activity. The relatively low specific activity
of these peptides, at present, precludes their immediate
progress to in-vivo studies as lead agents. Preliminary
Table 4 In-vitro Survival of H460 Human Non-small Cell Lung Cancer and Normal Diploid Human Fibroblasts Following
Exposure to Cyclic Amphiphilic Analogues of PRGPRP
Cell Viability
Compound Dose Human Non-small Cell Lung Cancer Normal Diploid Fibroblasts
XVI. (THR53) Cyc-[FPPRGPRPVKLALKLALK] 200 μM _ _ _ + + +
XVII. (THR53C) Cyc-[FPPRRPGPVKLALKLALK] 200 μM + + + + + +
XVIII. (THR54) Cyc-[PRGPRPVALKLALKLAL] 100 μM _ _ _ + + +
XIX. (THR79) Cyc-[PRGPRPvalklalklal] 50 μM _ _ _ + + +
XX. Cyc-[PR(Me)GPRPVALKLALKLAL] 200 μM + +/- N/D
XXI. Cyc-[PRGPR(Me)PVALKLALKLAL] 200 μM ++ + N/D
XII. Cyc-[PR(Me)GPR(Me)PVALKLALKLAL] 200 μM + + + N/D
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Figure 4 Time course of cell death and morphological appearances of a range of cancers of different histologies exposed to 200 μM
THR53. A. Time course of loss of viability in H460 human non-small cell lung cancer, H1299 human non-small cell lung cancer and MCF-7
human breast cancer cells exposed to 200 μM THR53. MRC5-hTERT cells were unaffected by 200 μM THR53. Viability assessed by Trypan Blue
exclusion of MRC5-hTERT, H460, H1299 and MCF-7 cells in the presence or absence of the compound, trypsinised off and stained at the
appropriate time point. Each data point is the mean of results from triplicate wells (Solid lines - Live cells, Broken lines - Dead Cells; Blue -
Control, Red - THR53 200 μM). B. Morphgological appearances of ubiquitous response to 200 μM THR53 of: SK-BR-3 human breast cancer, H460
human non-small cell lung cancer, SW620 human colorectal cancer and G361 malignant melanoma cells. C. Side by side quantification of H460
and MRC-5 cell viability assays at a single, 7 day, time point comparing THR53 (PRGPRP in cyclic amphiphilic cassette) and THR53C (PRRPGP in
cyclic amphiphilic cassette) after initial exposure to compounds at a concentration of 200 μM.
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pharmacokinetic experiments with a maximum tolerated
dose of THR53 (Institute of Cancer Therapeutics, Uni-
versity of Bradford, UK) have shown low plasma levels
which were not persistent, indicating that there is a
need for new PRGPRP congeners of higher specific
activity. Having identified a novel therapeutic strategy
and demonstrated proof of principle with the first and
second generation compounds, medicinal chemistry stu-
dies to produce a further generation of compounds with
improved PK are being undertaken.
The findings presented here of broad anticancer activ-
ity without toxicity to normal cells accompanied by a
putative companion theranostic of altered Cdk1/Cdk4
ratios, however, merit continued investigation with the
potential for development of a new range of anticancer
therapeutics.
PRGPRP-containing peptides could be causing cancer cell
death by necrosis
Therapeutic stresses are generally understood to result in
three possible types of programmed cell death (PCD);
namely apoptosis (PCD I), autophagy (PCD II) or necrosis
(PCD III) [36]. Following exposure to 200 μM THR53, the
morphological appearances of two histologically distinct
cancer cell lines, H460 and RT112 (Figures 5B, C) are not
B. RT112
Control
THR53 200 M
C. H460
Control
THR53 200 M
Control
THR53 200 M
A. MRC5-hTERT
90h
10h
10h
30h
30h
30h
30h
60h
60h
5h
5h
9h
9h
33h
33h
45h
45h 90h
Figure 5 Time Lapse Photomicrography of MRC5-hTERT, RT112
human bladder cancer and H5460 human non-small cell lung
cancer following exposure toTHR53. Cells were incubated in
Ham’s F12 + 10% FCS (control medium) or medium + 200 μM
THR53. Morphological changes of vacuolation + cellar swelling are
seen in RT112 at 33 hours after exposure to THR53 and in H460 at
90 hours after exposure to THR53. There was no evidence of cell
blebbing or fragmentation. (see also videos)
Table 5 Human in-vitro cancer cell lines showing a
complete response to 200 μM THR53
Cell Line Source Histology
MGHU-1 ICR Sutton, Surrey Carcinoma Bladder
H460 ATCC HTB-177NCI Non-Small Cell Lung Carcinoma
SW620 ATCC CCL-227 Adenocarcinoma Colon
G361 ECACC 88030461 Melanoma
MCF7 ECACC 86012803 Adenocarcinoma Breast
H1299 ATCC CRL-5803 Non-Small Cell Lung Carcinoma
SK-BR-3 ATCC HTB-30 Adenocarcinoma Breast
A375 ATCC CRL-1619 Melanoma
U2OS ATCC HTB-96 Osteosarcoma
SW480 ECACC 87092801 Adenocarcinoma Colon
RT112 ECACC 85061106 Carcinoma Bladder
MCF7 10%FCS Control
MCF7 10%FCS + 200 μM THR53
MCF7 10%FCS + THR53 200 μM
MCF7 1.0%FCS Control
MCF7 1.0%FCS +THR53 200 μM
0 1
0 1
A
Cdk1
PRRPGP PRGPRP
Time after exposure (Days)
0 1 3 5 7 10 0 1 3 5 7 10
Cdk4
C Day 1
0 100 200
Cdk1
Cdk4
Actin
THR53 Dose ( M)
D
B
96h Control
0 1023 0 1023
96h THR53 100 M
0 1023
96h CQ 25 M
Figure 6 THR53 cancer cell killing requires cells to have
entered the cell division cycle, does not cause perturbation of
cycling cells but does alter relative Cdk1/Cdk4 co-expression.
A. Macroscopic appearances of cycling THR53-treated MCF-7 human
breast cancer cells in medium + 10% FCS (left hand panels)
compared to the same cells held outside the cell cycle in medium
+ 0.1%FCS (right hand panel) B. DNA histograms of H460 human
non-small cell lung cancer cells exposed to THR53 or an autophagy-
inducing dose of 50 μM chloroquine. C. Sequential Western blots of
Cdk1 and Cdk4 expression in RT112 human bladder cancer cells at
0 - 10 days after exposure to 5 mM linear, end-capped, PRGPRP. D.
Western blot of Cdk1 and Cdk4 expression in H460 human non-
small cell lung cancer cells 24 hours after exposure to 100 μM and
200 μM THR53.
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dissimilar to phase contrast images of Caco-2, human
colon adenocarcinoma cells undergoing autophagic cell
death 3 days after exposure to imiquimod [37]. There was,
however, no evidence of autophagy in the Cyto-ID Green
assay of H460 human lung cancer cells treated with a 100
μM dose of THR53 which causes 50% death in this cell line
(Figure 7C). Moreover, morphological or DNA histogram
manifestations of apoptosis were not seen after exposure to
THR53. Apoptosis is an energy-requiring, cellular, autodes-
tructive process dependent on ATP; in contrast to necrosis
which is not ATP-dependent [36,38]. Depletion of ATP as
seen in H460 cells treated with 100 μM THR53 would be
expected to direct cell death towards necrosis rather than
apoptosis. Moreover, H460 and two other cancer cell lines
(H1299 and MCF-7) exhibited similar time courses for
necrosis as assayed by trypan blue exclusion.
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Figure 7 Induction of changes in mitochondrial function, total cellular protein, ATP activity and autophagy in H460 human non-small
cell lung cancer cells following exposure to THR53 or chloroquine. A. Treatment with THR53 showing selective inhibition of ATP at 96
hours after initial exposure. B. Treatment of H460 with Chloroquine results in non-specific changes in all cell death parameters at 96 hours after
initial exposure. C. THR53 treatment of H460 non-small cell lung cancer cells does not induce autophagy.
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Disruption of Cdk1/Cdk4 co-expression following
exposure to 200 μM THR53
An extensive literature search has failed to provide an
explanation for the relative elevation of Cdk1 in dying
cancer cells following drug exposure and whether or not
this might be related to necrotic cell death. Cdk1 eleva-
tion does, however, indicate that PRGPRP and its analo-
gues are not apparently causing any defect in the
classical Cdk4 downstream pathway. If proved consis-
tent, however, such a change in Cdk1/Cdk4 co-expres-
sion could potentially provide a theranostic biomarker
for PRGPRP analogue therapeutic efficacy.
Potential protein-protein interactions involving PRGPRP
In keeping with its congruence to the PxxP motif
described in binding to SH3 domains [39], PRGPRP is
likely involved in protein-protein interactions. Singularly,
however, the charged arginines of PRGPRP lie within,
rather than flanking, the proline-rich core.
Despite the discovery route described here, however,
and the intriguing location of PRGPRP within an exter-
nalised loop of Cdk4 not present in the homologous
regions of Cdk2, Cdk6 or Cdk1, there is no direct evi-
dence that this amino-acid sequence is functional within
the whole normal Cdk4 protein. Resolving this will be
the subject of future investigations. In addition, although
it appears that the distance of the external loop contain-
ing the PRGPRP amino-acid sequence from the site of
Cyclin D1 binding in the Cdk4 protein (Figure 1C) and
the failure of conditional expression of the whole Cdk4
molecule to induce pRb phosphorylation (Figure 1B) or
alter cell cycle phase distribution (Figure 6B), make it
unlikely that PRGPRP itself and its congeners affect
cyclin D1 binding and subsequent pRb phosphorylation,
we have not directly confirmed this.
Putative mechanism of PRGPRP cytotoxicity
The lack of efficacy of THR53 killing in quiescent MCF-
7 breast cancer cells maintained in complete medium
plus 0.1% FCS (Figure 6A), suggests that human cancer
cells may need to have entered the cell cycle to become
vulnerable to THR53. Nonetheless no perturbation of
cell cycle phase distribution was seen. Based on all our
currently available data, therefore, we hypothesise that,
to supplement its classical cyclin-dependent kinase
activity when bound to cyclin D, Cdk4 might also
embody a kinase-independent signalling mechanism to
release sufficient energy to enable cell division. Thus a
putative function of the FPPRGPRPVQSV domain may
be to promote the increase in ATP that is required to
carry out cell division. A requirement for the
FPPRGPRPVQSV region of Cdk4 to provide energy for
cancer cell division could also provide an explanation
for the fact that Cdk4 rather than Cdk2 or Cdk6 appears
to be the mandatory cyclin-dependent kinase for carci-
nogenic malignant transformation.
Cancer cells in a metabolically active state of relentless
cell division are highly energy dependent, deriving this
energy from anaerobic metabolism as opposed to the
aerobic metabolism of normal cells [40,41]. PRGPRP at
high concentration may cause selective cancer cell
necrosis by inhibition of anaerobic ATP provision, either
as an isolated activity of presently unknown mechanism,
or by competitive inhibition of the FPPRGPRPVQSV
region of Cdk4. Disruption of energy provision, in this
manner, might be expected to show the uniform selec-
tive cancer cell killing effect reported here. The detailed
molecular interactions involved in these results require
considerable further investigation. Nonetheless, ubiqui-
tous, cancer-selective, killing by PRGPRP compounds
may potentially herald new forms of anticancer therapy
at the proteomic level.
Materials and methods
Cell culture, clonogenic assays and Western blotting
have previously been described [20,20]. All cell lines
were from certified sources [24,30]. In addition to
experiments in The Cancer Sciences Division of The
University of Southampton some cell biology assays
were carried out by Horizon Discovery Services (260
Cambridge Science Park, Milton Road, Cambridge, CB4
0WE). THR53, THR54 and THR79 (Synthesised by
Polypeptide Laboratories Inc. 365 Maple Avenue Tor-
rance CA 90503 USA) were prepared by dissolving in
10 μL of DMSO followed by introduction into 10 ml of
tissue culture medium with rapid mixing, diluted to the
required dose in tissue culture medium, introduced to
the appropriate cells and left in situ for the duration of
the experiment. Primary antibodies for Western blotting
were: Cdk1 - mouse monoclonal sc-54 at 1/250, Cdk2
sc-748 at 1/250, Cdk4 - rabbit polyclonal sc-260 at 1/
250, Cdk6 - rabbit polyclonal sc-260 at 1/250, pRb 105
rabbit polyclonal sc-50 at 1/1000, pRb 110 (hyperpho-
sphorylated) rabbit polyclonal sc-32824 at 1/500 (All
from Santa Cruz Biotechnology Inc, Bergheime Str 89-2,
69115 Heidelberg, Germany). The ecdysone-inducible
CDK4 expression system in 2780 human ovarian carci-
noma cells was constructed by cloning CDK4 cDNA
from a previously described pcDNA3 vector [20] into a
pIND vector (Invitrogen). Linearised constructs of this
vector were transfected into 2780 cells with FuGENE™
reagent (Roche). Resistant colonies were selected by 2
weeks exposure to G418, expanded, and tested for
increased Cdk4 expression following exposure to 1 μM
muristerone.
Mitochondrial function (alamar blue) NCI-H460 cells
were grown in Ham’s F12 media supplemented with
10% FCS. Cells were harvested and added to 96-well
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plates at densities of 250-1000. Compounds were made
up from stock solutions and added directly to cells at
the concentrations indicated. Cells were grown with
compound for the indicated time at 37°C, 5% CO2, in a
humidified atmosphere. Alamar Blue 10% (v/v) was then
added and incubated for a further 4 h, and fluorescent
product detected using the BMG FLUOstar plate reader.
The media only background was subtracted and the
data analysed as appropriate.
Total cellular protein (sulphorhodamine B assay) was
carried out on alamar Blue treated cells once this assay
had been completed. Control medium/alamar blue were
removed and 200 μl PBS was added. Cells were fixed by
layering 25% (v/v) of a 50% TCA solution on top and
incubating for 1 h at 4°C. Wells were rinsed with water
and allowed to air dry. Cells were then stained in 0.4%
SRB solution, before rinsing with 1% acetic acid and air
drying. Incorporated dye was solubilised in 10 mM Tris
and absorbance measured at 565 nm and 690 nm.
Absorbance measurements at 690 nm were subtracted
from the 565 nm readings to correct for multi-well plate
absorbance.
Cellular ATP levels (CellTiter-Glo assay) Cells were
grown, seeded and compound-treated as for the alamar
Blue assay. A volume of the CellTiter-Glo reagent equal
to the volume of cell culture media was added to the
cells. Plates were mixed for 2 min on an orbital shaker
to induce cell lysis before the plate was incubated at
room temperature for 10 min to stabilize the signal. The
luminescent signal was measured and the media only
background was subtracted.
Autophagy Assay was performed as recommended by
the manufacturers’ instructions (Enzo ENZ-51031-
K200). Briefly, H460 cells were seeded into 6 well plates
at 2.5 × 105 and 1 × 105 cells/well. Immediately after
cell plating, chloroquine or THR53 were added at the
concentrations indicated. Following compound treat-
ment, cells were washed once in PBS and resuspended
in x1 Cyto-ID Green autophagy detection reagent and
incubated at room temperature for 30 min. Immediately
prior to analysis, propidium iodide (PI) solution was
added to the cell suspension at a final concentration of
2.5 μg/ml, to assess cell death. Analysis was carried out
using FACSCalibur (BD Biosciences). Cyto-ID Green
autophagy reagent was measured in the FL-1 channel
(530/30 nm bandpass filters with excitation at 488 nm)
and PI measured in the FL-3 channel (670 nm longpass
filters with excitation at 488 nm).
Necrosis Assay Cells were plated in triplicate in 96
well plates at concentrations of 500 cells per well
(HT1299, MCF-7) or 1000 cells per well (H460, MRC5-
hTERT) in the presence or absence of the relevant com-
pound and assessed by Trypan Blue exclusion At 2,3,4
and 7 days after plating. To assay, cells were trypsinised
off, stained with trypan blue in isotonic medium and live
and dead cells separately counted visually by haemocy-
tomter. Each data point is the mean of results from tripli-
cate wells (Solid lines - Live cells, Broken lines - Dead
Cells; Blue - Control, Red - THR53 200 μM).
Structural Studies
The amino acid sequences used in this work were
obtained from the Swiss-Prot and TrEMBL databases,
maintained at the Expasy molecular biology server (http://
ca.expasy.org/). The sequence similarity searches were
performed using BLAST [42] maintained by the Swiss
Institute for Biology (SIB), using default parameters unless
otherwise stated. The sequences for potential templates
were obtained from the PDB via a Blast search. Global
multiple sequence alignments were performed using the
program ClustalX [43]. Secondary structure alignments
were performed using Swiss PDB-viewer v3.7 [44].
Modelling Work
The x-ray crystal structures of Cdk6 and Cdk2 were
obtained from the PDB. The suitability of the structures
as templates was assessed by the program WHAT-
CHECK [45] The program JACKAL [46] was used to
build the homology model. The program Profix, a utility
program distributed with JACKAL, was used to replace
those residues and atoms missing from the structures.
The models were constructed as follows:
1. Using the global multiple alignment, corrected for
secondary structure, the program mutates non-con-
served residues while retaining the original backbone
conformation. The mutated residues were subjected
to energy minimisation to remove atom clashes. The
minimisation was performed in torsion angle space,
using the fast torsion angle minimiser implemented
in JACKAL. The energy function uses the
CHARMM22 all atom force field [47]. Insertions
and deletions are then performed, with the bonds
closed using a random tweak method. The results
are again minimised.
2. The secondary structure was assigned using a
DSSP-like routine [48].
3. Prediction of the identified loop regions was per-
formed as follows: a) First, the original backbone seg-
ment was deleted and replaced by a new segment that
was made by generating a large number of random
backbone conformations, which were then closed
using a random tweak method, b) the closed confor-
mers were subjected to energy minimisation using the
fast torsion angle minimiser, c) the side chains were
then modelled using a large rotamer library of 3222
rotamers in 10° bins and subjected to further minimi-
sation, d) the best candidate, the conformer with the
Warenius et al. Molecular Cancer 2011, 10:72
http://www.molecular-cancer.com/content/10/1/72
Page 13 of 16
lowest energy, was retained, and a further round of
conformation sampling was performed about the new
conformation, e) the final structure was subjected once
again to energy minimisation.
4. The secondary structure elements were then
refined by again sampling through a backbone rota-
mer library, but with the original rotamer retained
in the sampling. To retain the hydrogen-bonding
network of the existing secondary structure, a large
energy penalty was incurred by any conformation
that broke an existing hydrogen bond (hydrogen
bonds are defined as in DSSP). The lowest energy
conformation was retained. The side chains were
then built in a similar way.
5. The final model was minimised using the torsion
angle minimiser.
6. After the construction of the model, it was sub-
jected to 500 steps of steepest descent full energy
minimisation using AMBER, with the parm96 force
field [49]. The polar hydrogen atoms were added by
WHATIF [50] after optimising the hydrogen-bond
network.
7. Steps 1-6 were repeated until no further improve-
ment in the model was obtained.
At points it was also necessary to manually tweak the
structures. This was performed through the Swiss PDB-
viewer. The final models were assessed for accuracy and
quality by the programs WHAT-CHECK and Swiss PDB-
viewer. The threading energy given by Swiss PDB-viewer
is based on the potential of mean force developed by
Sippl et al. [51]. The molecular mechanics energy was
calculated using the GROMACS96 force field [52] and
was also implemented in Swiss PDB-viewer.
Additional material
Additional file 1: Time Lapse Photomicrographic Video of H460
human non-small lung cancer cells exposed in-vitro to 200 μM
THR53. H460 cells were grown in the presence of 200 μM THR53 in
Ham’s F12 medium + 10% FCS. Micrographic video frames at ×40
magnification were taken at 20 minute intervals and are shown at 7
frames per second. In contrast to control H460 cells, grown in the same
medium in the absence of THR53 (see below), although undergoing
repeated cell divisions, treated H460 cells show progressive cell death
throughout succesive divisions, typified by cellular swelling, vacuolation
and disintegration. There is no morphological evidence of apoptosis.
Additional file 2: Time Lapse Photomicrographic Video of H460
human non-small lung cancer cells growing in normal medium in-
vitro in the absence of THR53. H460 cells were grown in Ham’s F12
medium + 10% FCS without THR53. Micrographic video frames at ×40
magnification were taken at 20 minute intervals and are shown at 7
frames per second. Control H460 cells, undergo normal repeated cell
divisions without evidence of cell death.
Additional file 3: Time Lapse Photomicrographic Video of MRC5-
hTERT immortalised normal human fibroblasts exposed in-vitro to
200 μM THR53. MRC5-hTERT immortalised normal human fibroblasts
were grown in the presence of 200 μM THR53 in Ham’s F12 medium +
10% FCS. Photomicrographic video frames at ×40 magnification were
taken at 20 minute intervals and are shown at 7 frames per second. In
contrast to H460 cells exposed to THR53, MRC5-hTERT cells although
showing slight slowing in their division rate compared to untreated
MRC5-hTERT cells, progressed through a series of cell divisions without
any evidence of cell death.
Additional file 4: Time Lapse Photomicrographic Video of Control
MRC5-hTERT immortalised normal human fibroblasts growing in
the absence of THR53.THR53. Control MRC5-hTERT immortalised
normal human fibroblasts were grown in the absence of THR53.
Photomicrographic video frames at ×40 magnification were taken at 20
minute intervals and are shown at 7 frames per second. MRC5-hTERT
immortalised normal human fibroblasts went through a series of
repeated cell divisions without evidence of cell death.
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